Remy Sukhija
Nessuna posizione attualmente
Patrimonio netto: - $ in data 31/03/2024
Profilo
Remy Sukhija worked as the Chief Executive Officer at ODH, Inc. from 2018 to 2019.
Prior to that, he was the Executive Director at Merganser Biotech Australia Pty Ltd.
in 2015-2016 and the Chief Operating Officer at Merganser Biotech, Inc. in the same period.
From 2017 to 2020, he served as the Senior Vice President-North America at Otsuka Pharmaceutical Development & Commercialization, Inc. Currently, he is the Chief Commercial Officer & Senior Vice President at Madrigal Pharmaceuticals, Inc. from 2020 to 2023.
Mr. Sukhija completed his undergraduate degree from the University of Akron.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Precedenti posizioni note di Remy Sukhija
| Società | Posizione | Fine |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 25/09/2023 |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The private company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Corporate Officer/Principal | 01/03/2020 |
ODH, Inc.
 ODH, Inc. Medical/Nursing ServicesHealth Services Part of Otsuka Holdings Co., Ltd., ODH, Inc. is a healthcare technology company that provides insightful solutions through data and analytics to their clients and individuals they serve. The private company is based in Princeton, NJ. | Chief Executive Officer | 01/06/2019 |
Merganser Biotech, Inc.
 Merganser Biotech, Inc. BiotechnologyHealth Technology Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA. | Chief Operating Officer | 01/12/2016 |
| Merganser Biotech Australia Pty Ltd. | Director/Board Member | 01/12/2016 |
Formazione di Remy Sukhija
| University of Akron | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Part of Otsuka Holdings Co., Ltd., Otsuka Pharmaceutical Development & Commercialization, Inc. is a healthcare company that was founded in 2007. The private company is based in Princeton, NJ. The company is driven by their purpose and defined by their beliefs. | Health Technology |
ODH, Inc.
ODH, Inc. Medical/Nursing ServicesHealth Services Part of Otsuka Holdings Co., Ltd., ODH, Inc. is a healthcare technology company that provides insightful solutions through data and analytics to their clients and individuals they serve. The private company is based in Princeton, NJ. | Health Services |
| Merganser Biotech Australia Pty Ltd. | |
Merganser Biotech, Inc.
Merganser Biotech, Inc. BiotechnologyHealth Technology Merganser Biotech, Inc. engages in the development of of hepcidin mimetic peptides as new medicines for the treatment of hematological and iron overload diseases. The company was founded by Brian R. MacDonald and Gene Merutka in 2011 and is headquartered in Newtown Square, PA. | Health Technology |
- Borsa valori
- Insiders
- Remy Sukhija
